Ignite Creation Date:
2025-12-24 @ 3:23 PM
Ignite Modification Date:
2026-02-24 @ 12:14 AM
Study NCT ID:
NCT02967692
Status:
TERMINATED
Last Update Posted:
2025-09-18
First Post:
2016-11-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Melanoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Spartalizumab (PDR001) | View |
| None | dabrafenib | View |
| None | trametinib | View |
| None | melanoma | View |
| None | immunotherapy | View |
| None | PD 1 inhibitor | View |
| None | anti PD1 | View |
| None | PD-1 | View |
| None | anti-PD-1 | View |
| None | combination treatment | View |
| None | malignant skin cancer | View |
| None | skin cancer | View |
| None | BRAF V600 | View |
| None | unresectable BRAF V600 mutated melanoma | View |
| None | metastatic BRAF V600 mutated melanoma | View |